James Bradner
Executive Vice President of Research & Development, Amgen · Stanford Health Care
Credentials: · ·
History
- Present
- 2002–2005
Hematology and Medical Oncology
- 1999–2002
Internal Medicine
Research
Selective inhibition of BET bromodomains
Nature · 2010 · Last of 25 authors · 3,504 citations
Selective inhibition of tumor oncogenes by disruption of super-enhancers
Cell · 2013 · 2,432 citations
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
Cell · 2011 · 2,410 citations
19 papers
12 papers
- RP
12 papers
12 papers
11 papers
9 papers
8 papers
7 papers
Grants
- 2009–2020
Mechanisms, Prevention and Treatment of Chronic Graft-vs.-Host Disease
National Cancer Institute · P01
Project lead · $639.4K · Dana-Farber Cancer Inst
- 1997–2020
Development of Novel Therapeutic Strategies in Human Leukemias
National Cancer Institute · P01
Project lead · $2.4M · Dana-Farber Cancer Inst
- 2003–2019
National Cancer Institute · P50
Project lead · $1.2M · Dana-Farber Cancer Inst
- 2015–2019
Regulation of Chromatin Signaling in Heart Failure by the BRD4 Bromodomain Protein.
National Heart, Lung, and Blood Institute · R01
PI · $1.8M · University of Colorado Denver